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Awareness campaigns of Atrial Fibrillation as an opportunity for early detection by 66 
pharmacists - an international cross-sectional study 67 
 68 
Abstract  69 
Background: Atrial fibrillation (AF) accounts for up to one third of strokes, one of the 70 
lead mortality causes worldwide. The European Society of Cardiology guidelines 71 
recommend opportunistic screening as a means to increase the odds of early detection and 72 
institution of appropriate treatment according to risk factors identified. However, in most 73 
countries there are various barriers to effective uptake of screening, including low 74 
awareness. The Atrial Fibrillation Association is a patient association engaged with 75 
raising awareness of AF. Establishing a partnership with the International Pharmacists for 76 
Anticoagulation Care Taskforce, we set as goals to test a model for raising awareness of 77 
AF involving pharmacists globally; and to identify barriers and enablers to its 78 
implementation.  79 
Methods: A cross-sectional study was conducted during the Arrhythmia Alliance World 80 
Heart Rhythm Week. Pharmacists from 10 countries invited individuals (≥40 years; 81 
without anticoagulation therapy of AF) to participate in the awareness campaign. 82 
Participants agreeing were engaged in the early detection of AF (EDAF) using pulse 83 
palpation. Individuals with rhythm discrepancies were referred and prospectively 84 
assessed to have information on the proportion of confirmed diagnosis, leading to 85 
estimate the detection rate. Interviews with country coordinators explored barriers and 86 
enablers to implementation. 87 
Results: The study involved 4,193 participants in the awareness campaign and 2,762 in 88 
the EDAF event (mean age 65.3±13.0), of whom 46.2% individuals were asymptomatic, 89 
recruited across 120 sites. Most common CHA2DS2-VASc risk factor was hypertension. 90 
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Among 161 patients referred to physician, feedback was obtained for 32 cases, of whom 91 
12 new arrhythmia diagnoses were confirmed (5 for AF, 2 for atrial flutter), all among 92 
elders (≥65 years). Qualitative evaluation suggested a local champion to enable 93 
pharmacists’ success; technology enhanced engagement amongst patients and increased 94 
pharmacists’ confidence in referring to physicians; interprofessional relationship was 95 
crucial in success. 96 
Conclusion: This study suggests involving pharmacists is beneficial for greater outreach 97 
of awareness campaigns. Effective communication pathways for inter-professional 98 
collaboration are needed to gain full benefits of EDAF. 99 
 100 
Keywords: Atrial fibrillation; awareness; pharmacists; pulse check; early detection of 101 
disease  102 
 103 




Mass screening at the population level is one means for early detection of a disease, within 106 
the scope of public health initiatives. The StrokeStop study involved thousands of 107 
individuals screened for atrial fibrillation (AF).1 However, demonstrating that 108 
opportunistic screening is more cost-effective led to consider new venues.2 Community 109 
pharmacies are conveniently located, easily accessible and serve many individuals, 110 
including asymptomatic, making pharmacists positioned to undertake initiatives for the 111 
early detection and management of chronic diseases.3,4 Various early detection events 112 
have been shown feasible and effective when delivered through pharmacies5, including 113 
the early detection of AF (EDAF), tested in Australia, New Zealand, Canada and the 114 
UK.6-10 Considering the high prevalence of AF in the elders, the risk of thromboembolic 115 
events (mainly stroke), the existence of effective medicines, and the success of previous 116 
EDAF in pharmacies, the development of pharmacist-patient partnerships in awareness 117 
on a global scale seemed natural.6  118 
 119 
Methods 120 
Aims and objectives 121 
The primary aim of this study was to test a model for raising awareness of AF involving 122 
pharmacists globally and to use this event for opportunistic EDAF. A secondary objective 123 
included identifying the enablers and barriers to program implementation. 124 
 125 
Design and procedures 126 
The International Pharmacist for Anticoagulation Care Taskforce (iPACT) created a 127 
partnership with the Atrial Fibrillation Association (AF Assoc) & Arrhythmia Alliance 128 
(A-A) to promote the active involvement of pharmacists in awareness campaigns. A 129 
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cross-sectional study was conducted during the global A-A World Heart Rhythm week, 130 
in June 2017, involving pharmacists from ten countries. A pilot study, to determine 131 
feasibility, was undertaken in 2016 using 56 recruitment sites across five countries 132 
(Canada, New Zealand, Portugal, Spain and the UK). Five additional countries were 133 
included in the main study (Czech Republic, France, Hong Kong, Hungary and 134 
Switzerland). All individuals aged ≥40 years during the awareness event entering sites 135 
involved (community pharmacies, hospital outpatient clinics, community day care centres 136 
and nursing homes) were invited to participate in the EDAF.12-14 Patients with known AF 137 
not on anticoagulant therapy were also addressed because this event was considered an 138 
opportunity to motivate pharmacists to engage further in medicines optimisation. Patients 139 
diagnosed with AF and prescribed any anticoagulant (except if for a limited time for the 140 
indication of venous thromboembolism including oral and parenteral drugs) were 141 
excluded.  142 
 143 
Public Involvement 144 
This study arose from an initiative led by the AF Assoc and the A-A. Both are registered 145 
charities with a longstanding successful history in publicising pulse awareness 146 
campaigns, for which all materials have been developed jointly between healthcare 147 
professionals and citizens, considering patients’ preferences. This study aimed to go 148 
beyond awareness by contributing to EDAF. To reach such aim, the   research questions, 149 
the study design and procedures were developed, refined and agreed by a steering group 150 
of four individuals, including one cardiologist, one patient representative, one clinical 151 
pharmacist and one researcher. The overall results of the study have been disseminated 152 
to study participants using social media and Health Pioneers report, issued annually by 153 
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the AF Assoc and the A-A. A podcast mentioning the global event has also been widely 154 
spread. 155 
 156 
Previous training and materials used  157 
iPACT developed an online module to support education of pharmacists about AF and its 158 
early detection. Pharmacists advertised the event two weeks ahead providing oral 159 
information and displaying posters. Once the campaign started, pharmacists used pulse 160 
taking as recommended by the latest European Society of Cardiology (ESC) guidelines 161 
to identify and refer suspects of AF11, informed individuals to manually take their pulse 162 
to promote self-care, and increase awareness of AF. Participants used educational 163 
materials developed by AF Assoc and A-A; non-English translations for the project were 164 
developed jointly between A-A, AF Assoc and iPACT. Pharmacists engaged patients in 165 
EDAF when agreement on data storage was reached, which was made possible using a 166 
secure web-based application.  The pulse was manually checked, using a standardised 167 
procedure developed by A-A and endorsed by the UK Department of Health15 and made 168 
available on iPACT’s website and in the online module. Subsequently, an assessment of 169 
symptoms and risk factors was made and in some countries, the pulse check was 170 
confirmed using a single-lead portable ECG device (Kardia AliveCor)®. Whenever an 171 
abnormal heart rate or rhythm were detected, when having symptoms suggestive of AF 172 
or in the presence of a high CHA2DS2-VASc score, pharmacist referred the patient to a 173 
physician. All referred individuals were requested to return and provide feedback on the 174 
medical consultation. The decision to undertake additional diagnostic tests, particularly a 175 
12-lead ECG, or to initiate therapy was left to the physicians’ discretion, even in countries 176 
where pharmacists independently prescribe. Pharmacists were not compensated for 177 








The primary outcomes reflecting the functionality of EDAF model were the detection rate 182 
of AF and the proportion of confirmed diagnosis. Further analysis focused on the barriers 183 
and enablers to program implementation by way of interviews with all country 184 
coordinators in March 2018. The referral pathway and the influence of the setting, country 185 
and communication format on the effectiveness of EDAF were explored. The theoretical 186 
hypothesis leading the analysis was based in Freedman et al, where questions posed to 187 
identify targets for EDAF where benefits are substantial include: Whom to screen? Where 188 
to screen? How to screen? 16  189 
 190 
Data analysis 191 
Quantitative data analysis conducted in SPSS v.24 included non-parametric tests (Chi-192 
square and Mann-Whitney) to compare proportions or rankings of population subgroups 193 
by setting, considering a p-value of 0.05. Qualitative data analysis focused on constant 194 
comparative analysis to understand the enablers for effective referral pathways. Each 195 
coordinator was sent an interview guide to discuss all aspects of the process with 196 
pharmacists from their respective countries. Interviews were conducted by SA with the 197 
coordinators, advising the purpose, using an adapted interview guide from the AF-study6 198 
(supplement 1). These interviews were audio-recorded, transcribed verbatim and 199 
analysed manually line-by-line and coded by LN for emergent themes using Charmaz’s 200 
iteration of constant comparative analysis.17. Analyses were interpreted by LN and FC 201 
until cohesive and conceptually clear themes were identified, and discussed amongst all 202 
authors to reach consensus on interpretation of content and principal themes.  203 
  204 
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Results  205 
The pilot study undertaken in 2016 involved 1,717 individuals, and suggested the project 206 
to be realistic, while shedding light on improvements needed to reach further 207 
individuals.18  208 
The upscaling study involved 4,193 participants. Individuals with no demographic data 209 
(n=1,259), and those not meeting predefined inclusion criteria (n=172) were excluded. 210 
The largest contribution was from the UK (n=1,259; valid data from 592 individuals), 211 
although the country contributing the most valid data was Portugal (n=958), followed by 212 
Spain (n=432), Hong Kong (n=351), Canada (n=128), Hungary (n=118) and New 213 
Zealand (n=78). Some countries used this opportunity to test the referral pathway using a 214 
small sample of recruiting sites and involving few individuals (Switzerland n=48; Czech 215 
Republic n=45; France n=12). The final analysis included 2,762 individuals, mainly 216 
recruited in community pharmacies, with smaller numbers in other settings (Figure 1).  217 
Globally 120 recruitment sites were used, including 104 community pharmacies, three 218 
community care centres, two hospitals, and one nursing home. Some characteristics were 219 
similarly distributed across sites, while others were clearly influenced by the site, 220 
particularly CHA2DS2-VASc score. Most individuals were female (68%), with a greater 221 
gender inequality where the elder prevailed (p<0.05). Mean age was 65.3 ±13.0, while 222 
nursing homes displayed a significantly higher mean age (p<0.05). Nearly half the 223 
individuals were asymptomatic for heart difficulties, with a slightly higher proportion of 224 
asymptomatic found at the day care centre. The most common symptom found in all 225 
settings was tiredness and the most common stroke CHA2DS2-VASc risk factor was 226 
hypertension. The least common was previous myocardial infarction, followed by stroke. 227 
In contrast, patients from nursing homes more frequently reported previous history of 228 
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stroke, compared to others settings (p<0.05). The mean CHA2DS2-VASc score was 2.6 229 
in the overall sample, varying significantly between settings (p<0.05) [Table 1].  230 
Overall, 161 patients were referred to the physician (5.8%), with a lower proportion 231 
among those submitted only to manual pulse taking (5.2%; 74/1,416) compared to those 232 
where manual pulse was confirmed by the one-lead device (6.5%; 87/1,346). The 233 
proportion of referrals ranged from 3.0% in the UK to 8.9% in Spain, the most common 234 
being around 6.0-7.1% (Switzerland, Hong Kong, Czech Republic and New Zealand). 235 
Portugal was an exception, where few of the pharmacies had access to the device but the 236 
overall trend was to use solely manual pulse taking. In this country, referral was higher 237 
for those pharmacists using portable devices (11.1% versus 4.2%). However, when only 238 
manual pulse was used, more frequently a confirmed diagnosis was obtained from the 239 
physician (n=10/1,416 vs n=2/1,346).  240 
Considering the subsample, in which the one-lead portable ECG device was used 241 
(n=1,346; 48.7%), 60 individuals were identified as having “possible AF” (4.5%). There 242 
were additionally 14 individuals with known AF, three of whom were medicated with 243 
antiplatelet agents, actionable AF (0.2%).19 These individuals were advised to consult a 244 
physician.  245 
The detection rate was different across health care settings, and in line with the changes 246 
in CHA2DS2-VASc score (Table 2).  247 
The analysis was restricted to individuals aged ≥ 65, justified by previous research20, and 248 
where the portable ECG device was used, justified by the higher validity.21 Among 249 
referred patients (n=161), feedback was obtained for 32 cases (19.9%). In total 12 new 250 
arrhythmia diagnoses were confirmed, five for AF (0.32% among the elderly). All five 251 
cases were identified among elders in the community pharmacy, two following manual 252 
pulse check and three subsequently confirmed by the portable ECG device. There were 253 
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two additional cases of atrial flutter, also among the elderly in community pharmacy and 254 
confirmed by the physician. Two cases of bradycardia were detected, one resulting from 255 
iatrogenic reaction to beta-blockers.  256 
 257 
Qualitative results 258 
The interviews suggest that identification of a local champion was instrumental in 259 
enabling community pharmacists to successfully undertake EDAF. The key enabling 260 
factors facilitated by the local champion was finding innovative ways to combine with 261 
existing services and enabling flexibility in service provision leading to new opportunities 262 
to identify AF (Figure 2).  263 
 264 
Local champion 265 
One local champion was even able to offer EDAF to people on public transport: 266 
“One of my rural colleagues checked pulses in a group of older Maori women in the back 267 
of the bus going to town”. (New Zealand) 268 
Combine with existing services 269 
Managing existing services was viewed as a useful way to engage with EDAF and 270 
enhance recruitment; patients liked the addition of EDAF to medication review, or to 271 
other cardiovascular risk factor clinics. Multiple participants commented that combining 272 
these services provided benefit and increased patient acceptance: 273 
“In the context of a medication review or other professional service, patients were more 274 
likely to accept AF screening. Patients often said they felt that the medication review was 275 
more comprehensive with the AF screen than without”. (Canada) 276 
Enhanced role 277 
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This ability to combine services provided a useful enhanced role for pharmacists and they 278 
were notably more willing to engage with these services if they had prior experience of 279 
offering enhanced services. They reported having the required skills and expertise to 280 
engage in these services:  281 
 “My team’s previous involvement in the national Pharmaceutical care program of 282 
hypertension enabled us to actively participate in the pulse awareness campaign quite 283 
easily”… “In fact, probably creating links with other existing programs would maximise 284 
the efficiency in practice”. (Hungary) 285 
Conducting these events gave pharmacists a greater understanding about the potential for 286 
a wider scope of practice and felt participation could be motivational: 287 
“The events have been a good way to motivate the staff, to show pharmacists that there 288 
are other valuable roles they can take on.  It was also useful for intern pharmacists to 289 
participate in, to get them used to touching patients and in providing more general 290 
medical, rather than pharmaceutical knowledge.” (New Zealand). 291 
Flexibility of setting 292 
Others struck a note of caution about the rapid increase in role diversity in pharmacists 293 
and the changing environment in which pharmacists are working: 294 
 “The scope of practice of pharmacists is quickly expanding. We just had a decree 295 
published enabling us to offer more services, namely in health promotion and disease 296 
prevention (e.g. HIV screening).  This could be a very interesting additional service in 297 
the future, provided the referral pathway is improved.” (Portugal) 298 
Bright inviting patient materials 299 
A key area for increased engagement was the provision of bright inviting patient 300 
materials, which a local champion could play a key role in tailoring for the local setting.  301 
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“We used two billboards at the pharmacy door and had them on sight during the entire 302 
week…we also used Facebook and twitter to advertise the Heart Rhythm week”. (Spain) 303 
Text dense page booklets 304 
The patient materials could also act as barriers, because of their text-dense, complex 305 
language; for the older, with lower health-literacy, or finding the information 306 
inaccessible: 307 
“The large detailed information sheet on AF is very wordy and off-putting to many 308 
patients.” (New Zealand) 309 
Language barrier 310 
“Most of our elders (1/3) could not read and that hindered the use of leaflets”. (Hong 311 
Kong) 312 
Finding AF 313 
Successfully identifying AF acted as a major enabler to sustained service provision as it 314 
increased the sense that there was a value in providing the service, and enabled a sense of 315 
camaraderie between the GPs and the pharmacists conducting the screening: 316 
“The first patient we screened in our initial AF week initiative turned out to have 317 
undiagnosed asymptomatic AF. I had previously informed the GPs of the initiative and 318 
they were supportive. We had agreed on a point of referral should a pharmacist find an 319 
irregular pulse. An hour after we sent the patient for review the clinical director came 320 
down to tell us that an ECG had confirmed AF. After that the GPs also upped their 321 
screening rate for the week”. (New Zealand) 322 
Simplicity of screening and online resources 323 
Pharmacists commented on the ease of technology and the enhanced engagement 324 
provided amongst patients: 325 
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“The screening for AF with the Kardia® Mobile ECG-Monitor was very easy. In addition, 326 
patients were very curious and most patients asked, also agreed to be checked”. 327 
(Switzerland) 328 
While most pharmacists commented on the positive engagement, there were some 329 
patients who felt that their GPs were already providing these services, or did not really 330 
see the point of engaging in EDAF in pharmacy. It was younger more technologically 331 
aware patients who were interested in the tests, while those more likely to benefit showed 332 
a greater reluctance to participate:  333 
“Patients who were more reluctant to use technology were less keen to be involved in the 334 
AF screening. Often younger, more tech savvy patients were the patients who were more 335 
eager to be assessed. Other patients felt that their physician already provided such 336 
services during their annual physical.” (Canada) 337 
Better communication 338 
The patient relationship with the physician was crucial for the success (or otherwise) of 339 
pharmacy based EDAF, as physicians were influential, with some pharmacists reporting 340 
a good relationship with their local GPs enabling better service provision.  341 
“We are fortunate where we work as we already have an established relationship working 342 
closely with our clinicians and this was another opportunity to extend our clinical activity 343 
to improve the care or in the case detection of a condition for people with AF”. (UK) 344 
Cardiologists unwilling to relinquish tasks 345 
Some physicians resisted pharmacists taken on EDAF and to pharmacist-led initiatives in 346 
general, which acted as local barriers to uptake: 347 
“Some physicians are quite strongly against these pharmacist-led initiatives, which make 348 
implementation much more difficult.” (Hungary) 349 
Pharmacists found the EDAF process less rewarding when feedback was not obtained: 350 
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“In Hungary, there was absolutely no feedback whatsoever from physicians, so 351 
confirmation of any referral was impossible to obtain…a long way needs to be worked 352 
here” (Hungary) 353 
When a good relationship existed, pharmacists commented that conducting EDAF 354 
enhanced their relationship with local care providers, and particularly liked the enhanced 355 
communication: 356 
“Overall, (it was a) very rewarding experience. Patients, particularly those with 357 
underlying cardiovascular disease, were very appreciative that we were offering such a 358 
service… The team also saw the value of the screen and often helped in the recruitment 359 
of patients…it led to collaboration between pharmacy technicians, assistants and 360 
pharmacists.” (Canada) 361 
Financial constraints 362 
A major challenge remained in considering sustaining a service like this, in particular 363 
relating to finances for undertaking EDAF, which acted as a key barrier globally: 364 
“Whilst this is easily deliverable in community pharmacies, this needs to be commissioned 365 
for this to be undertaken routinely”. (UK) 366 
 367 
Discussion 368 
A large number of individuals were involved, suggesting community pharmacies offer a 369 
convenient and accessible venue for awareness campaigns. The demographics include a 370 
high proportion of patients with chronic medical conditions and contribute to the high 371 
detection rates previously shown.19,22 This international roll-out experience showed the 372 
enormous potential of such initiatives raising the awareness on AF to over 4,000 373 
individuals across ten countries. The involvement of 2,762 individuals in EDAF was also 374 
an achievement, although the detection rate of new cases was only 0.18% restricting to 375 
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those physician confirmed, but could be as high as 4.5% assuming device detected AF. 376 
This rate varied across settings, likely related to the number of co-morbidities indicated 377 
by the CHA2DS2-VASc score and age contributing to the progressive increase in the 378 
incidence of AF.23 The weighted average for detection rate of new cases in screened 379 
groups across all studies reported by European Heart Rhythm Association is 0.9%.24  380 
Because opportunistic screening is recommended for patients aged ≥ 65,11 we have 381 
recalculated the detection rate, finding a detection rate of 1.8% in the ambulatory setting, 382 
in line with the 1.4% previously reported.20 This value could be underestimated, because 383 
we used single-time point screening; and particularly in some countries, the healthcare 384 
system’s organization leads to delayed response. Conversely, the validity of methods used 385 
is likely to generate some false positives. 386 
The experience gained from this initiative suggests that involving pharmacists from 387 
various settings has benefits, namely reaching younger individuals where raising 388 
awareness about AF is effective in health promotion. The higher proportion of suspected 389 
AF detected in day care centres and nursing homes is not surprising as the older are more 390 
likely to have AF and other arrhythmias. Previous studies have demonstrated high cost-391 
effectiveness of using community pharmacies to screen for AF using portable devices.5 392 
We are aware that more episodic pulse checks would increase the rate of detection.25 393 
Using pulse palpation has benefits in access, and limitations associated with the 394 
technique’s validity.5 Regular implementation in practice is needed to achieve full 395 
potential of the pharmacist delivered EDAF. The confidence of pharmacists to advise 396 
patients on anticoagulation varies by region.26 This implies that while for some countries 397 
an online training could suffice, for others intensive face-to-face training with practical 398 
components would be necessary. The possibility of involving practice nurses and clinic 399 
receptionists in EDAF was also explored elsewhere showing differences in confidence 400 
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addressing patients.27 This supports the need for tailored education, especially in multi 401 
country initiatives where levels of practice vary widely. Pharmacists need additional 402 
training in communication skills, particularly on disclosing information, an aspect to be 403 
addressed in the future in cooperation with the medical and civil society organizations. 404 
Our qualitative data suggests a need for investing in efficient referral pathways to ensure 405 
patients identified with AF receive anticoagulation where appropriate. The differences in 406 
referral rates could result from various factors, including access to portable ECG devices, 407 
patient’s unwillingness, more advanced practice levels26 or stronger inter-collaboration 408 
networks in place. The main difficulties in gaining the benefits could be access to 12-lead 409 
ECG assessment and physician acceptance of the EDAF. Initiatives aimed at a direct 410 
referral to a one-stop AF clinic are already being explored.28 Approaches combining 411 
EDAF with existing services were suggested, e.g. immunization, medication review or 412 
cardio checks.  413 
Participants thought that perceiving an unmet need would increase the recognition of the 414 
value of this initiative. As such, in the future we intend to explore individuals’ previous 415 
experience with the health care services.   416 
The easy use and previous validity data drove the choice of device. However, 417 
unavailability in some countries limited standardization of the procedure. A high 418 
proportion of unclassified (8.4%) and unreadable (0.4%) traces were found, repeated, but 419 
when unsolved, led to referral for investigation. It is worth highlighting that some of these 420 
devices are currently marketed directly to consumers, which may have implications for 421 
patients and for the health care system. In fact, we believe having healthcare professionals 422 
as entry points to the system is beneficial and pharmacists working collaboratively are 423 
key to ensure signs, symptoms and false positives are identified, avoiding unnecessary 424 
use of medical services and patients’ concerns.  425 
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Although this study is valuable due to the innovative approach to pharmacists’ traditional 426 
role and the number of countries involved, limitations exist. We opted to provide a unified 427 
process for recruitment without sample size estimation, where all countries were 428 
motivated to participate, regardless of their resources. This option led to greater outreach 429 
but for a lower ability to engage in subgroup analysis of data. We used manual pulse as a 430 
means for raising awareness but also for EDAF. However, we noticed pharmacists with 431 
access to portable devices felt more confident to refer subjects with possible AF to 432 
physicians. Only around a quarter of suspected cases were referred. The reasons 433 
abovementioned for low referral are not applicable to actionable AF, where individuals 434 
were referred using an unstructured procedure attributable to the setting (hospital waiting 435 
area), leaving the decision to consult the physician on the patient with no possible 436 
feedback. This suggests this venue is effective for awareness but not suitable for EDAF. 437 
The more frequent confirmation of diagnosis when only manual pulse was taken might 438 
result from a greater perceived need to come to a diagnosis. 439 
In some countries, there is no access to medical history; hence, patient reports were used, 440 
potentially leading to misclassification bias. Missing data may result from difficulty 441 
understanding the English data collection form, an aspect to be addressed in the future 442 
creating a multilingual app. The main drawback seems to be the low proportion of 443 
confirmed diagnosis, which led us to highlight the detection rate identified by the mobile 444 
single-lead ECG device and a need for investing in efficient referral pathways in future 445 
work to ensure patients identified with AF receive anticoagulation where appropriate. The 446 
true detection rate is much lower, but we believe it results mainly from a culture of 447 
interprofessional collaboration that needs boosting in many countries. It is worth stressing 448 
that results are not generalizable elsewhere, as health system’s functioning and 449 
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Our data shows the enormous potential of involving multiple stakeholders in awareness 454 
events, as we have reached over 4,000 individuals across ten countries in only one week. 455 
The ability to engage in EDAF seems however to be lower. Although nearly 3,000 456 
individuals were involved, the main barrier identified was the healthcare pathway that 457 
would ensure a physician subsequently assesses positive cases. Our data suggests that it 458 
might not be the setting per se to influence the detection rate, but the infrastructure in 459 
place, namely the possibility to use portable devices but above all the existing 460 
communication channels between pharmacists and physicians. Other barriers seem easier 461 
to tackle, namely the availability of devices or more intense training. However, the 462 
improvement of healthcare systems’ functionality calls for multiple efforts, which must 463 
involve the public, various healthcare professionals and policy-makers. 464 
 465 
List of Abbreviations 466 
A-A: Arrhythmia Alliance  467 
AF: Atrial fibrillation 468 
AF Assoc: Atrial Fibrillation Association  469 
CHA2DS2-VASc: Atrial Fibrillation Stroke Risk (Congestive heart failure history; 470 
hypertension; advanced age; diabetes; stroke or thromboembolism history; vascular 471 
disease history; sex)  472 
CHF: Congestive Heart Failure 473 
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DM: Diabetes Mellitus 474 
ECG: Electrocardiogram  475 
EDAF: Early Detection of Atrial Fibrillation 476 
ESC: European Society of Cardiology  477 
GPs: General Practitioners  478 
iPACT: International Pharmacists for Anticoagulation Care Taskforce 479 
MI: Myocardial Infraction 480 
UK: United Kingdom 481 
HIV: Human Immunodeficiency Virus 482 
PAD: Peripheral Artery Disease 483 
SD: Standard Deviation 484 
SOB: Shortness of Breath 485 
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